NGEN

NervGen Pharma Corp.

Price Chart

No historical data available

Latest Quote

$2.32

+0.11 (+4.98%)
Current Price
Previous Close $2.21
Open $2.21
Day High $2.37
Day Low $2.10
Volume 1,057,596
Fetched: 2026-09-02T12:56:32
Stock Information
Note: Financial values converted from CAD to USD
Shares Outstanding 107.52M
Cash Equivalents $62.37M
Net Income $-44.53M
Sector Healthcare
Industry Biotechnology
Market Cap $249.45M
EPS (TTM) $-0.57
Exchange NCM
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About NervGen Pharma Corp.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

📰 Latest News
No news articles available at the moment. Check back later for updates on NGEN.
Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $18,077,351 $18,147,195 $12,813,613 $16,596,651
Other Income Expense $-13,963,128 $81,800 $-3,716,119 $1,885,602
Net Non Operating Interest Income Expense $240,329 $585,742 $396,498 $-225,760
Operating Expense $18,077,351 $18,147,195 $12,813,613 $16,596,651
General And Administrative Expense $8,052,911 $6,730,284 $6,942,706 $4,568,785
Interest Expense - - $0 $370,928
Interest Expense Non Operating - - $0 $370,928
Total Other Finance Cost - - - -
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Net Interest Income $240,329 $585,742 $396,498 $-225,760
Interest Income $240,329 $585,742 $396,498 $145,168
Normalized Income $-17,837,022 $-17,561,453 $-12,417,114 $-16,822,411
Net Income From Continuing And Discontinued Operation $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Net Income Common Stockholders $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Net Income $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Net Income Including Noncontrolling Interests $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Net Income Continuous Operations $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Pretax Income $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Interest Income Non Operating $240,329 $585,742 $396,498 $145,168
Operating Income $-18,077,351 $-18,147,195 $-12,813,613 $-16,596,651
Depreciation Amortization Depletion Income Statement $0 $20,185 $71,052 $52,882
Depreciation And Amortization In Income Statement $0 $20,185 $71,052 $52,882
Depreciation Income Statement $0 $20,185 $71,052 $52,882
Per Share
Diluted EPS $-0.44 $-0.26 $-0.27 $-0.28
Basic EPS $-0.44 $-0.26 $-0.27 $-0.28
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-4,074,005 $-18,168,592 $-8,992,975 $-16,368,508
Total Unusual Items $-13,963,128 $81,800 $-3,716,119 $1,885,602
Total Unusual Items Excluding Goodwill $-13,963,128 $81,800 $-3,716,119 $1,885,602
Reconciled Depreciation $40,218 $60,402 $104,519 $82,975
EBITDA (Bullshit earnings) $-18,037,133 $-18,086,792 $-12,709,094 $-14,482,905
EBIT $-18,077,351 $-18,147,195 $-12,813,613 $-14,565,880
Diluted Average Shares $52,136,769 $48,526,086 $42,736,799 $37,949,898
Basic Average Shares $52,136,769 $48,526,086 $42,736,799 $37,949,898
Diluted NI Availto Com Stockholders $-31,800,150 $-17,479,654 $-16,133,234 $-14,936,808
Gain On Sale Of Security $-13,963,128 $81,800 $-3,716,119 $1,885,602
Research And Development $10,024,439 $11,396,726 $5,799,855 $11,974,984
Selling General And Administration $8,052,911 $6,730,284 $6,942,706 $4,568,785
Other Gand A $3,175,175 $1,909,190 $2,067,264 $2,206,852
Salaries And Wages $4,877,736 $4,821,094 $4,875,443 $2,361,933
Fetched: 2026-09-01
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $2,211,240 $1,522,074 $-1,823,518 $9,391,774
Total Assets $16,729,479 $14,045,644 $9,540,507 $17,209,225
Total Non Current Assets $294,924 $341,173 $519,361 $523,792
Goodwill And Other Intangible Assets $294,924 $335,141 $375,358 $310,955
Other Intangible Assets $294,924 $335,141 $375,358 $310,955
Current Assets $16,434,555 $13,704,471 $9,021,146 $16,685,433
Other Current Assets $462,500 $76,162 $11,771 -
Current Deferred Assets $0 $295,713 $0 -
Receivables $58,259 $299,348 $180,350 $19,481
Other Receivables $18,247 $195,081 $180,112 -
Taxes Receivable $40,012 $104,268 $238 -
Cash Cash Equivalents And Short Term Investments $15,913,797 $12,516,470 $8,404,184 $16,183,083
Cash And Cash Equivalents $15,907,764 $12,446,384 $8,404,184 $16,183,083
Prepaid Assets - $516,777 $424,841 $482,869
Accounts Receivable - - $180,350 $19,481
Cash Financial - - - $16,183,083
Debt
Total Debt $6,032 $76,119 $142,134 $204,314
Long Term Debt And Capital Lease Obligation $0 $6,032 $76,119 $142,134
Current Debt And Capital Lease Obligation $6,032 $70,086 $66,015 $62,180
Liabilities
Total Liabilities Net Minority Interest $14,223,315 $12,188,429 $10,988,667 $7,506,496
Total Non Current Liabilities Net Minority Interest $0 $6,032 $76,119 $142,134
Current Liabilities $14,223,315 $12,182,397 $10,912,548 $7,364,362
Other Current Liabilities $10,860,200 $8,550,609 $8,495,855 $4,852,622
Payables And Accrued Expenses $2,374,688 $2,723,738 $1,838,628 $2,449,561
Payables $19,797 $24,103 $2,393,922 $1,806,510
Other Payable $19,797 $24,103 - -
Accounts Payable - - $2,393,922 $1,442,978
Equity
Common Stock Equity $2,506,164 $1,857,215 $-1,448,160 $9,702,729
Total Equity Gross Minority Interest $2,506,164 $1,857,215 $-1,448,160 $9,702,729
Stockholders Equity $2,506,164 $1,857,215 $-1,448,160 $9,702,729
Gains Losses Not Affecting Retained Earnings $34,051,577 $17,319,735 $12,406,670 $8,520,042
Retained Earnings $-105,786,953 $-73,987,257 $-56,332,599 $-40,199,596
Other
Ordinary Shares Number $57,411,081 $50,696,042 $42,964,215 $42,367,882
Share Issued $57,411,081 $50,696,042 $42,964,215 $42,367,882
Tangible Book Value $2,211,240 $1,522,074 $-1,823,518 $9,391,774
Invested Capital $2,506,164 $1,857,215 $-1,448,160 $9,702,729
Working Capital $2,211,240 $1,522,074 $-1,891,402 $9,321,071
Capital Lease Obligations $6,032 $76,119 $142,134 $204,314
Total Capitalization $2,506,164 $1,857,215 $-1,448,160 $9,702,729
Capital Stock $74,241,540 $58,524,737 $42,477,768 $41,382,282
Common Stock $74,241,540 $58,524,737 $42,477,768 $41,382,282
Long Term Capital Lease Obligation $0 $6,032 $76,119 $142,134
Current Capital Lease Obligation $6,032 $70,086 $66,015 $62,180
Pensionand Other Post Retirement Benefit Plans Current $982,395 $837,963 $512,050 -
Current Accrued Expenses $2,354,891 $2,699,635 $1,838,628 $643,050
Investments And Advances $0 $6,032 $0 -
Other Investments $0 $6,032 $0 -
Net PPE $0 $0 $144,003 $212,837
Gross PPE $0 $0 $144,003 $212,837
Other Short Term Investments $6,032 $70,086 $0 -
Dueto Related Parties Current - - $316,131 $363,532
Other Properties - - $144,003 $212,837
Fetched: 2026-09-01
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-14,055,006 $-12,138,995 $-8,243,773 $-12,834,014
Operating Activities
Operating Cash Flow $-14,055,006 $-12,138,995 $-8,141,849 $-12,818,802
Cash Flow From Continuing Operating Activities $-14,055,006 $-12,138,995 $-8,141,849 $-12,818,802
Operating Gains Losses $13,341,930 $315,095 $3,692,282 $-1,871,051
Investing Activities
Investing Cash Flow $72,747 $42,436 $-100,086 $-15,212
Cash Flow From Continuing Investing Activities $72,747 $42,436 $-100,086 $-15,212
Capital Expenditure - - $-101,923 $-15,212
Financing Activities
Issuance Of Capital Stock $12,170,440 $16,586,867 $0 $14,245,008
Financing Cash Flow $17,129,015 $16,358,607 $552,337 $16,319,917
Cash Flow From Continuing Financing Activities $17,129,015 $16,358,607 $552,337 $16,319,917
Net Other Financing Charges $-643,517 $-1,175,148 - $-93,013
Net Common Stock Issuance $12,170,440 $16,586,867 $0 $14,245,008
Common Stock Issuance $12,170,440 $16,586,867 $0 $14,245,008
Other
Repayment Of Debt $-72,747 $-72,747 $-72,747 $-54,561
Interest Paid Supplemental Data $0 $0 $0 $0
End Cash Position $15,907,764 $12,446,384 $8,404,184 $16,183,083
Beginning Cash Position $12,446,384 $8,404,184 $16,183,083 $12,202,298
Effect Of Exchange Rate Changes $314,624 $-219,848 $-89,301 $494,882
Changes In Cash $3,146,756 $4,262,047 $-7,689,598 $3,485,903
Proceeds From Stock Option Exercised $5,674,839 $1,019,635 $625,085 $2,222,483
Net Issuance Payments Of Debt $-72,747 $-72,747 $-72,747 $-54,561
Net Long Term Debt Issuance $-72,747 $-72,747 $-72,747 $-54,561
Long Term Debt Payments $-72,747 $-72,747 $-72,747 $-54,561
Net Intangibles Purchase And Sale $72,747 $42,436 $-97,870 $0
Sale Of Intangibles $72,747 $42,436 $0 -
Change In Working Capital $473,896 $604,430 $-173,243 $1,524,462
Change In Payables And Accrued Expense $-193,346 $884,696 $-53,691 $1,672,482
Change In Prepaid Assets $426,153 $-161,268 $41,318 $-174,672
Change In Receivables $241,090 $-118,998 $-160,869 $26,652
Changes In Account Receivables $241,090 $-118,998 $-160,869 $26,652
Stock Based Compensation $3,888,647 $4,353,425 $4,357,029 $2,000,178
Depreciation Amortization Depletion $40,217 $60,401 $104,517 $82,974
Depreciation And Amortization $40,217 $60,401 $104,517 $82,974
Amortization Cash Flow $40,217 $40,217 $33,467 $30,093
Amortization Of Intangibles $40,217 $40,217 $33,467 $30,093
Depreciation $0 $20,185 $71,051 $52,881
Gain Loss On Investment Securities $13,667,827 $97,999 $3,599,989 $-1,376,169
Net Foreign Currency Exchange Gain Loss $-325,898 $212,158 $92,293 $-494,882
Gain Loss On Sale Of PPE $0 $4,938 $0 -
Net Income From Continuing Operations $-31,799,696 $-17,479,404 $-16,133,003 $-14,936,595
Purchase Of Intangibles - $0 $-97,870 $0
Net PPE Purchase And Sale - $0 $-2,216 $-15,212
Sale Of PPE - $0 $1,837 $0
Purchase Of PPE - $0 $-4,053 $-15,212
Other Non Cash Items - $7,057 $10,568 $381,230
Change In Payable - - - $1,672,482
Change In Account Payable - - - $1,672,482
Fetched: 2026-09-01